Anorexia-Cachexia Syndrome (CS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Cachexia Syndrome (CS) is a multifactorial syndrome characterized by body weight loss, declining muscle mass and function, wasting, and inflammation of adipose tissues accompanied by metabolic dis-arrangement, anorexia, systemic inflammation, and insulin resistance. The clinical relevance of cachexia is shown by its impact on both the prognosis and the efficacy of treatment against the underlying disease as well as survival time and quality of life. Cachexia is typically associated with a number of underlying chronic degenerative diseases, such as cancer, chronic obstructive pulmonary disease (COPD), HIV, chronic heart failure, diabetes, liver failure, rheumatoid arthritis, and chronic kidney failure. Chronic conditions share several underlying mechanisms and ultimately have similar output, i.e., severe muscle wasting. However, the multifactorial origin of cachexia and its multisystem involvement made the study of this syndrome in the context of underlying chronic diseases. This is also characterized by an ongoing loss of skeletal muscle that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment.

·       The overall prevalence of Cachexia is ranged between 0.19% to 0.23% in the USA and in the EU the overall prevalence ranges between 0.28% to 0.32%.

 

Thelansis’s “Anorexia-Cachexia Syndrome (CS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Anorexia-Cachexia Syndrome (CS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Anorexia-Cachexia Syndrome (CS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Anorexia-Cachexia Syndrome (CS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Anorexia-Cachexia Syndrome (CS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Anorexia-Cachexia Syndrome (CS), Anorexia-Cachexia Syndrome (CS) market outlook, Anorexia-Cachexia Syndrome (CS) competitive landscape, Anorexia-Cachexia Syndrome (CS) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)